AXQ Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

AXQ Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,758	Closed	-$568K	–	634
2023 Q4	$568K	Buy	+1,758	New	+$551K	0.15%	242

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

AXQ Capital's BIO Position: Q1 2024 in Review

AXQ Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 1,758 shares — an estimated $568K sold.

AXQ Capital first reported a position in BIO in Q4 2023 and held it in 1 quarter. The position peaked at $568K in Q4 2023. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

AXQ Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
AXQ Capital sold 1,758 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $568K.
AXQ Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 1 quarter.
AXQ Capital's Bio-Rad Laboratories Class A position peaked at $568K in Q4 2023.
466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on AXQ Capital's 13F filing for Q1 2024, filed 14 May 2024.